ジェネリック医薬品市場：タイプ別、投与経路別、適応症別、薬剤別、流通別-2025-2030年の世界予測

ジェネリック医薬品市場の2023年の市場規模は2,991億6,000万米ドルで、2024年には3,162億7,000万米ドルに達すると予測され、CAGR 5.91%で成長し、2030年には4,474億5,000万米ドルに達すると予測されています。

ジェネリック医薬品市場の範囲と定義には、特許保護が切れた先発医薬品をベースに開発された医薬品が含まれ、知的財産権を侵害することなく複数のメーカーによる生産が可能です。ジェネリック医薬品の必要性は、その手頃な価格と入手しやすさにあり、高価な先発医薬品に代わる費用対効果の高い代替品を提供することで、ヘルスケアコストの削減と患者アクセスの拡大に貢献しています。その用途は、糖尿病や高血圧などの慢性疾患から急性感染症まで、幅広い治療領域に及んでおり、病院、診療所、小売薬局での大きな存在感を示しています。最終用途には、個々の患者、ヘルスケアプロバイダー、費用対効果の高い治療オプションを優先する政府のヘルスケアシステムなどが含まれます。この市場に影響を与える主な成長要因としては、慢性疾患の有病率の上昇、新興国におけるヘルスケア支出の増加、ジェネリック医薬品の迅速な承認を促す規制環境の整備などが挙げられます。

成長の機会は、ヘルスケア・インフラが拡大している新興国の未開拓市場や、特に生物学的製剤の特許切れが予想されるバイオシミラー分野に存在します。企業は、戦略的提携、製造能力、ターゲットを絞ったマーケティングに投資することで、こうした機会を活用することができます。しかし、激しい市場競争、厳しい規制要件、医薬品の品質やリコールに関する問題などの制約が、成長の妨げとなる可能性があります。また、価格圧力や、収益性と値ごろ感のバランスを保つ必要性からも課題が生じています。

イノベーションと研究開発には、ドラッグデリバリーシステムの進歩、複雑なジェネリック医薬品の開発、製造プロセスの持続可能性などが含まれます。ニッチな治療領域に注力し、医薬品開発と最適化のためにAIとビッグデータを活用することで、市場開拓に弾みをつけることができます。市場力学はダイナミックで競争的であり、規制の変化や市場の需要に常に適応する必要があります。こうした力学を活用するため、企業は堅牢な品質管理システムを優先し、特殊なジェネリック医薬品に投資することで、混雑した市場環境の中で差別化を図る必要があります。

市場力学：急速に進化するジェネリック医薬品市場における重要な市場洞察の解明

ジェネリック医薬品市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の有病率の上昇と費用対効果の高い医薬品へのニーズ
  • ジェネリック医薬品に対する政府の好意的支援
  • オンライン薬局を通じたジェネリック医薬品の入手可能性の増加
• 市場抑制要因
  • 患者や医師によるブランド薬志向
• 市場機会
  • ジェネリック医薬品の開発に伴う継続的な研究開発活動
  • ジェネリック医薬品を製造するための特許満了と戦略的長期提携の増加
• 市場の課題
  • 品質と製造のばらつきに関する懸念

ポーターのファイブフォース：ジェネリック医薬品市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、ジェネリック医薬品市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ジェネリック医薬品市場における外部からの影響の把握

外部マクロ環境要因は、ジェネリック医薬品市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ジェネリック医薬品市場における競合情勢の把握

ジェネリック医薬品市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスジェネリック医薬品市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ジェネリック医薬品市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ジェネリック医薬品市場における成功への道筋を描く

ジェネリック医薬品市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大の可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の増加と費用対効果の高い医薬品の必要性
    • ジェネリック医薬品に対する政府の好意的な支援
    • オンライン薬局を通じてジェネリック医薬品の入手性が増加
  • 抑制要因
    • 患者と医師によるブランド医薬品の好み
  • 機会
    • ジェネリック医薬品の開発に関連する進行中の研究開発活動
    • 特許の期限切れと製造のための戦略的な長期パートナーシップの増加ジェネリック医薬品
  • 課題
    • 品質と製造のばらつきに関する懸念
• 市場セグメンテーション分析
  • タイプ：複雑で慢性的な症状の治療への応用拡大
  • 流通：利便性、アクセス性、競争力のある価格設定により、オンライン薬局が好まれる傾向が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ジェネリック医薬品市場：タイプ別

• シンプルジェネリック
• 専門ジェネリック

第7章 ジェネリック医薬品市場：投与経路別

• 吸入可能
• 注射可能
• オーラル

第8章 ジェネリック医薬品市場適応症別

• がん
• 心血管疾患
• 中枢神経系疾患
• 糖尿病
• 消化器疾患
• ホルモンと関連疾患
• 感染症
• 呼吸器疾患

第9章 ジェネリック医薬品市場薬物別

• アセタゾラミド
• アシトレチン
• アトルバスタチン
• アジスロマイシン
• カルバマゼピン
• シタロプラム
• クロピドグレル
• ドネペジル
• エスシタロプラム
• エソメプラゾール
• フルチカゾン
• ガバペンチン
• ヒドロクロロチアジド
• レボチロキシン
• リシノプリル
• ロサルタン
• オメプラゾール
• ポサコナゾール
• ロスバスタチン
• セルトラリン
• シンバスタチン
• タムスロシン
• ワルファリン

第10章 ジェネリック医薬品市場配布元

• 病院薬局
• オンライン薬局
• 小売薬局

第11章 南北アメリカのジェネリック医薬品市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のジェネリック医薬品市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのジェネリック医薬品市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • BDRファーマ、真菌感染症のジェネリック医薬品を3分の1の価格で発売
  • アムニール社、ザイレム（オキシバトナトリウム）の認可ジェネリックを発売、5つの複合ジェネリックのFDA承認を取得
  • メディプラスヘルスサービスが自社ブランドのジェネリック医薬品を発売
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Alkem Laboratories Ltd.
• Amneal Pharmaceuticals Inc
• Aspen Holdings
• Aurobindo Pharma Limited
• Baxter International Inc.
• Cipla Ltd
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• Endo International plc.
• Fresenius SE & Co. KGaA.
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Glenmark Pharmaceuticals Ltd.
• Hikma Pharmaceuticals PLC.
• Johnson & Johnson Services, Inc.
• Lupin Limited
• Mylan N.V. by Viatris Inc.
• Pfizer Inc.
• Sandoz International GmbH by Novartis Group
• Sanofi S.A.
• STADA Arzneimittel AG
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Industries Ltd.
• Zydus Lifesciences Ltd

LIST OF FIGURES

• FIGURE 1. GENERIC DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. GENERIC DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GENERIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GENERIC DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GENERIC DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY SIMPLE GENERIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY SPECIALTY GENERIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GENERIC DRUGS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GENERIC DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GENERIC DRUGS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GENERIC DRUGS MARKET SIZE, BY HORMONES & RELATED DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL GENERIC DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL GENERIC DRUGS MARKET SIZE, BY ACETAZOLAMIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL GENERIC DRUGS MARKET SIZE, BY ACITRETIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL GENERIC DRUGS MARKET SIZE, BY ATORVASTATIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL GENERIC DRUGS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL GENERIC DRUGS MARKET SIZE, BY CITALOPRAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL GENERIC DRUGS MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL GENERIC DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL GENERIC DRUGS MARKET SIZE, BY ESCITALOPRAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL GENERIC DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL GENERIC DRUGS MARKET SIZE, BY FLUTICASONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL GENERIC DRUGS MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL GENERIC DRUGS MARKET SIZE, BY HYDROCHLOROTHIAZIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL GENERIC DRUGS MARKET SIZE, BY LEVOTHYROXINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL GENERIC DRUGS MARKET SIZE, BY LISINOPRIL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL GENERIC DRUGS MARKET SIZE, BY LOSARTAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL GENERIC DRUGS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL GENERIC DRUGS MARKET SIZE, BY POSACONAZOLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL GENERIC DRUGS MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL GENERIC DRUGS MARKET SIZE, BY SIMVASTATIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL GENERIC DRUGS MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL GENERIC DRUGS MARKET SIZE, BY WARFARIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 67. CANADA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. CANADA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. CANADA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. CANADA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 71. CANADA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 94. CHINA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. CHINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. CHINA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. CHINA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 98. CHINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 99. INDIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. INDIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. INDIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 102. INDIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 103. INDIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 104. INDONESIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. INDONESIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. INDONESIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. INDONESIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 108. INDONESIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 109. JAPAN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. JAPAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. JAPAN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. JAPAN GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 113. JAPAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. MALAYSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. MALAYSIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. MALAYSIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 118. MALAYSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 123. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. SINGAPORE GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 128. SINGAPORE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 144. VIETNAM GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 155. DENMARK GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. DENMARK GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 157. DENMARK GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 160. EGYPT GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. EGYPT GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 162. EGYPT GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 163. EGYPT GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 165. FINLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. FINLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. FINLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. FINLAND GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 169. FINLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 170. FRANCE GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. FRANCE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 172. FRANCE GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 173. FRANCE GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 174. FRANCE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 175. GERMANY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 176. GERMANY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 177. GERMANY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 178. GERMANY GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 179. GERMANY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 180. ISRAEL GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 181. ISRAEL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 182. ISRAEL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 183. ISRAEL GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 184. ISRAEL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 185. ITALY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. ITALY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 187. ITALY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 188. ITALY GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 189. ITALY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 190. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 191. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 192. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 193. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 194. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 195. NIGERIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 196. NIGERIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 197. NIGERIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 198. NIGERIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 199. NIGERIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 200. NORWAY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 201. NORWAY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 202. NORWAY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 203. NORWAY GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 204. NORWAY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 205. POLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 206. POLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 207. POLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 208. POLAND GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 209. POLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 210. QATAR GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 211. QATAR GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 212. QATAR GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 213. QATAR GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 214. QATAR GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 215. RUSSIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 216. RUSSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 217. RUSSIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 218. RUSSIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 219. RUSSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 220. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 221. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 222. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 223. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 224. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 225. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 226. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 227. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 228. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 229. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 230. SPAIN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 231. SPAIN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 232. SPAIN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 233. SPAIN GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 234. SPAIN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 235. SWEDEN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 236. SWEDEN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 237. SWEDEN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 238. SWEDEN GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 239. SWEDEN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 240. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 241. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 242. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 243. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 244. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 245. TURKEY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 246. TURKEY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 247. TURKEY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 248. TURKEY GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 249. TURKEY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 250. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 251. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 252. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 253. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 254. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 255. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 256. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 257. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 258. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 259. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 260. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 261. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Generic Drugs Market was valued at USD 299.16 billion in 2023, expected to reach USD 316.27 billion in 2024, and is projected to grow at a CAGR of 5.91%, to USD 447.45 billion by 2030.

The scope and definition of the generic drugs market involve pharmaceuticals developed based on brand-name drugs whose patent protection has expired, allowing production by multiple manufacturers without intellectual property infringement. The necessity of generic drugs lies in their affordability and accessibility, offering cost-effective alternatives to expensive brand-name medications, thereby instrumental in reducing healthcare costs and expanding patient access. Their application spans a vast array of therapeutic areas, from chronic conditions like diabetes and hypertension to acute infections, contributing to their substantial presence in hospitals, clinics, and retail pharmacies. The end-use scope includes individual patients, healthcare providers, and governmental healthcare systems prioritizing cost-effective treatment options. Key growth factors influencing this market include the rising prevalence of chronic diseases, increased healthcare expenditure in emerging economies, and a supportive regulatory environment that encourages the expedited approval of generics.

Opportunities for growth are present in untapped markets within developing countries where healthcare infrastructure is expanding, and in the biosimilar segment, particularly with the anticipated wave of biologic patent expirations. Companies can leverage these opportunities by investing in strategic collaborations, manufacturing capabilities, and targeted marketing. However, limitations such as intense market competition, stringent regulatory requirements, and issues related to drug quality and recalls can impede growth. Challenges also stem from pricing pressures and the need for maintaining a balance between profitability and affordability.

Innovation and research areas include advancements in drug delivery systems, development of complex generics, and sustainability in manufacturing processes. Market growth can be fueled by focusing on niche therapeutic areas and leveraging AI and big data for drug development and optimization. The nature of the generic drugs market is dynamic and competitive, with a constant need for adaptation to regulatory changes and market demands. To capitalize on these dynamics, organizations should prioritize robust quality management systems and invest in specialty generics to differentiate themselves in the crowded market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Generic Drugs Market

The Generic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of chronic diseases and the need for cost-effective medications
  • Favorable government support for generic drugs
  • Growing availability of generic drugs through online pharmacies
• Market Restraints
  • Preference for branded drugs by patients and physicians
• Market Opportunities
  • Ongoing R&D activities associated with the development of generic drugs
  • Increasing patent expirations and strategic long-term partnerships to manufacture generic drugs
• Market Challenges
  • Concerns associated with quality and manufacturing variability

Porter's Five Forces: A Strategic Tool for Navigating the Generic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Generic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Generic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Generic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Generic Drugs Market

A detailed market share analysis in the Generic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Generic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Generic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Generic Drugs Market

A strategic analysis of the Generic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Generic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Ltd., Amneal Pharmaceuticals Inc, Aspen Holdings, Aurobindo Pharma Limited, Baxter International Inc., Cipla Ltd, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Endo International plc., Fresenius SE & Co. KGaA., Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC., Johnson & Johnson Services, Inc., Lupin Limited, Mylan N.V. by Viatris Inc., Pfizer Inc., Sandoz International GmbH by Novartis Group, Sanofi S.A., STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Zydus Lifesciences Ltd.

Market Segmentation & Coverage

This research report categorizes the Generic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Simple Generic and Specialty Generic.
• Based on Route of Administration, market is studied across Inhalable, Injectable, and Oral.
• Based on Indication, market is studied across Cancer, Cardiovascular Diseases, Central Nervous System Disorders, Diabetes, Gastrointestinal Diseases, Hormones & Related Diseases, Infectious Diseases, and Respiratory Diseases.
• Based on Drug, market is studied across Acetazolamide, Acitretin, Atorvastatin, Azithromycin, Carbamazepine, Citalopram, Clopidogrel, Donepezil, Escitalopram, Esomeprazole, Fluticasone, Gabapentin, Hydrochlorothiazide, Levothyroxine, Lisinopril, Losartan, Omeprazole, Posaconazole, Rosuvastatin, Sertraline, Simvastatin, Tamsulosin, and Warfarin.
• Based on Distribution, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of chronic diseases and the need for cost-effective medications
    • 5.1.1.2. Favorable government support for generic drugs
    • 5.1.1.3. Growing availability of generic drugs through online pharmacies
  • 5.1.2. Restraints
    • 5.1.2.1. Preference for branded drugs by patients and physicians
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing R&D activities associated with the development of generic drugs
    • 5.1.3.2. Increasing patent expirations and strategic long-term partnerships to manufacture generic drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with quality and manufacturing variability
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Expanding applications of for treating complex and chronic conditions
  • 5.2.2. Distribution: Emerging preference for online pharmacies for convenience, accessibility, and competitive pricing
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Generic Drugs Market, by Type

• 6.1. Introduction
• 6.2. Simple Generic
• 6.3. Specialty Generic

7. Generic Drugs Market, by Route of Administration

• 7.1. Introduction
• 7.2. Inhalable
• 7.3. Injectable
• 7.4. Oral

8. Generic Drugs Market, by Indication

• 8.1. Introduction
• 8.2. Cancer
• 8.3. Cardiovascular Diseases
• 8.4. Central Nervous System Disorders
• 8.5. Diabetes
• 8.6. Gastrointestinal Diseases
• 8.7. Hormones & Related Diseases
• 8.8. Infectious Diseases
• 8.9. Respiratory Diseases

9. Generic Drugs Market, by Drug

• 9.1. Introduction
• 9.2. Acetazolamide
• 9.3. Acitretin
• 9.4. Atorvastatin
• 9.5. Azithromycin
• 9.6. Carbamazepine
• 9.7. Citalopram
• 9.8. Clopidogrel
• 9.9. Donepezil
• 9.10. Escitalopram
• 9.11. Esomeprazole
• 9.12. Fluticasone
• 9.13. Gabapentin
• 9.14. Hydrochlorothiazide
• 9.15. Levothyroxine
• 9.16. Lisinopril
• 9.17. Losartan
• 9.18. Omeprazole
• 9.19. Posaconazole
• 9.20. Rosuvastatin
• 9.21. Sertraline
• 9.22. Simvastatin
• 9.23. Tamsulosin
• 9.24. Warfarin

10. Generic Drugs Market, by Distribution

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Americas Generic Drugs Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Generic Drugs Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Generic Drugs Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. BDR Pharma launches generic drug for fungal infections at 1/3rd the cost
  • 14.3.2. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
  • 14.3.3. Mediplus Health Services launches own brand of generic medicines
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Alkem Laboratories Ltd.
• 3. Amneal Pharmaceuticals Inc
• 4. Aspen Holdings
• 5. Aurobindo Pharma Limited
• 6. Baxter International Inc.
• 7. Cipla Ltd
• 8. Dr. Reddy's Laboratories Ltd.
• 9. Eli Lilly and Company
• 10. Endo International plc.
• 11. Fresenius SE & Co. KGaA.
• 12. Gilead Sciences, Inc.
• 13. GlaxoSmithKline PLC
• 14. Glenmark Pharmaceuticals Ltd.
• 15. Hikma Pharmaceuticals PLC.
• 16. Johnson & Johnson Services, Inc.
• 17. Lupin Limited
• 18. Mylan N.V. by Viatris Inc.
• 19. Pfizer Inc.
• 20. Sandoz International GmbH by Novartis Group
• 21. Sanofi S.A.
• 22. STADA Arzneimittel AG
• 23. Sun Pharmaceutical Industries Ltd.
• 24. Teva Pharmaceuticals Industries Ltd.
• 25. Zydus Lifesciences Ltd